Is there a difference in the durability of CR based on the dosage of pembrolizumab used in metastatic melanoma?  

In this study, doses of 2mg/kg Q3wks, 10mg/kg Q3wks and 10mg/kg Q2wks were used. What did the majority of these patients in CR receive? 

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Ralph Lauren Center for Cancer Care and Prevention
That makes sense. Thank you!
Sign in or Register to read more